ProMetic Life Sciences Inc. (PLI) 2006年年度报告「TSX」.pdf

1、Closing PROMETIC LIFE SCIENCES INC.2006 ANNUAL REPORTbetweenperception2006 Highlights 1 Message to Shareholders 4ProMetic BioSciences Inc.10 ProMetic BioTherapeutics,Inc.14 ProMetic BioSciences Ltd18 BSafE Innovations Inc.22 Managements Discussion and Analysis of Operating Results and Financial Posi

2、tion25 Consolidated Financial Statements37 Notes to Consolidated Financial Statements 41The Annual Shareholders Meeting of ProMetic will be held on 2 May 2007,at 10:30 a.m.at the Museum of Fine Arts,Montreal,Quebec.CG3 inc.|Communications|GraphismePROMETIC LIFE SCIENCES INC.2006 ANNUAL REPORT1and re

3、alityIn 2006 a number of important milestones in theprogress of ProMetic Life Sciences were reached.Remarkably positive ongoing developments are positioning ProMetic for near-term profitability.With goals achieved in the marketplace,the laboratory and in clinical trials,the projections for the year

4、ahead are:Two of ProMetics business units reaching a cash neutral position with possible revenuesof$15 million;ProMetics proprietaryprocess for plasma fractionation to belicensed in Europe and Asia;ProMetic and its manufacturing partnerMacoPharma as the firstcompany in the worldwith a medical device

5、on the market that canremove prions fromhuman blood;andPotential value createdin clinical trials byProMetics two leaddrug candidates.PROMETIC LIFE SCIENCES INC.2006 ANNUAL REPORT2catalysts forgrowthPROMETIC LIFE SCIENCES INC.2006 ANNUAL REPORT3Proprietary technologies and proven productsWorld leader

6、 in newplasma fractionationprocesses,biopharma-ceutical purification,and pathogen removalA pioneer in strictly focused therapeutic advance in hematologyand oncologyPROMETIC LIFE SCIENCES INC.2006 ANNUAL REPORT4In 2006,on each and every front where our scientistswere engaged,ProMetic moved forward im